Cardinal Health (CAH) Jumps on Joint Venture with CVS Caremark

Shares of Cardinal Health (CAH) closed up $1.95 per share, at $66.22, up 3.03% on Tuesday. The increase came on the announcement of a joint venture with CVS Caremark (CVS) to form a generic drug sourcing unit. CVS was also up on the news, rising $1.27 to 68.00, or 1.90%.

Dublin, Ohio, based Cardinal Health is one of the world’s largest healthcare services companies, and is the 19th largest company in the Fortune 500.
The company improves the cost effectiveness of healthcare, working with pharmacies, hospitals and other healthcare facilities to focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability. The company has more than 33,000 employees worldwide.

Today’s joint venture announcement represents the formation of the largest generic sourcing entity in the US, which is also the world’s largest prescription drug market. The agreement represents a 50-50 joint venture between the two companies. The joint venture will be US-based and is expected to become operational by July 1, 2014. The initial term will be 10 years.

The agreement specifies quarterly payments of $25 million from each participating company over the life the agreement. These payments have an estimated after-tax present value of $435 million.

Neither Cardinal Health nor CVS Caremark have an obligation to contribute either physical assets or substantial funds to the initial capitalization of the new venture. The agreement is subject only to the completion of final documentation and customary closing conditions.

In a separate announcement, the two healthcare clients also agreed to a three-year extension of existing pharmaceutical distribution agreements through June, 2019. The previous agreements with CVS represent $24 billion of revenue, or about 22% of Cardinal Health’s total revenues of more than $107 billion.

The creation of the joint venture with CVS, as well as the extension of current agreements, is believed to at least partially offset the loss of similar agreements with Walgreen Co. (WAG), and Express Scripts, Inc. (ESRX), both of which were terminated earlier this year. Walgreen had been Cardinal Health’s second largest source of revenue, at 21% of total sales. Expressed Scripts previously contributed $9 billion in total revenue, and was the company’s third largest customer.

Cardinal Health currently trades at 15.1 times forward P/E, and is at the upper end of it‘s 52 week range of 40.49 - 67.75.

Other News About Cardinal Health 
Cardinal Health Achieves #57 Analyst Rank, Surpassing Express Scripts Holding
Cardinal Health has taken over the #57 spot from its former customer Express Scripts Holding.
Cardinal Health, Pharmacy Quality Solutions Help Community Pharmacies Benchmark Their Performance
Pharmacy Quality Solutions announced that they will collaborate with Cardinal Health.

Other Stocks in the News
MasterCard to Split Stock, Raise Dividend 83 Pct
MasterCard unveils 10-for-1 stock split, boosts dividend 83 percent, sets $3.5B buyback plan.
McDonald's November Sales Miss as U.S. Weakness Persists
Another sluggish month of sales at established outlets suggesting that McDonald's is losing U.S. market shares to rivals.

Copyright 2013 by, Inc. InvestorGuide has no control over the sites we link to, is not affiliated with these sites, and cannot take responsibility for their quality or suitability. The news, analysis, commentary and profile information is not meant to be comprehensive, and the data provided is not guaranteed to be accurate. WebFinance Inc., the publisher of this newsletter, is not a registered investment advisor or a broker/dealer. This is not a stock recommendation newsletter but rather a source for investment ideas, and we encourage you to fully research any company before considering investing. The opinions expressed herein are those of the author and do not necessarily represent the views of nor are they endorsed by WebFinance Inc. No employee of WebFinance has owned or currently owns any shares in the company described above. The above is neither an offer nor solicitation to buy or sell any securities. The trading of securities may not be suitable for all potential readers of this newsletter, and the purchase of stocks mentioned in this newsletter may result in the loss of some or all of any investment made. We recommend that you consult a stockbroker or financial advisor before buying or selling securities or making investment decisions. We are not responsible for claims made by advertisers and sponsors. Anyone who makes decisions based on what they read here does so at their own risk and cannot hold WebFinance Inc. (DBA, Inc.) or its employees responsible.

Published on Dec 11, 2013
By InvestorGuide Staff

Copyrighted 2020. Content published with author's permission.

Posted in ...